These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
419 related articles for article (PubMed ID: 17487379)
1. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. Fu X; Nakamori M; Tao L; Amato R; Zhang X Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379 [TBL] [Abstract][Full Text] [Related]
2. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. Li H; Dutuor A; Fu X; Zhang X J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169 [TBL] [Abstract][Full Text] [Related]
3. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Li H; Dutuor A; Tao L; Fu X; Zhang X Clin Cancer Res; 2007 Jan; 13(1):316-22. PubMed ID: 17200370 [TBL] [Abstract][Full Text] [Related]
4. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Nakamori M; Fu X; Pettaway CA; Zhang X Prostate; 2004 Jun; 60(1):53-60. PubMed ID: 15129429 [TBL] [Abstract][Full Text] [Related]
5. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Fu X; Tao L; Cai R; Prigge J; Zhang X Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513 [TBL] [Abstract][Full Text] [Related]
6. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Fu X; Tao L; Zhang X Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283 [TBL] [Abstract][Full Text] [Related]
7. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Nakamori M; Fu X; Meng F; Jin A; Tao L; Bast RC; Zhang X Clin Cancer Res; 2003 Jul; 9(7):2727-33. PubMed ID: 12855653 [TBL] [Abstract][Full Text] [Related]
8. [The construction of recombinant type I herpes simplex virus carrying GALV.fus gene and its antitumor effect in nude mice]. Zhu M; Yang JR; Jiang YQ; Chen SF; Fu XP; Tian ZD Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):152-6. PubMed ID: 21500543 [TBL] [Abstract][Full Text] [Related]
9. Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Fu X; Tao L; Li M; Fisher WE; Zhang X Clin Cancer Res; 2006 May; 12(10):3152-7. PubMed ID: 16707615 [TBL] [Abstract][Full Text] [Related]
10. Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. Li H; Zeng Z; Fu X; Zhang X Cancer Res; 2007 Aug; 67(16):7850-5. PubMed ID: 17699791 [TBL] [Abstract][Full Text] [Related]
12. Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide. Naito S; Obayashi S; Sumi T; Iwai S; Nakazawa M; Ikuta K; Yura Y Cancer Gene Ther; 2006 Aug; 13(8):780-91. PubMed ID: 16645620 [TBL] [Abstract][Full Text] [Related]
13. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice. Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626 [TBL] [Abstract][Full Text] [Related]
14. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Aghi M; Rabkin SD; Martuza RL Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749 [TBL] [Abstract][Full Text] [Related]
15. An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cells. Fu X; Tao L; Zhang X Gene Ther; 2007 Aug; 14(16):1218-25. PubMed ID: 17538637 [TBL] [Abstract][Full Text] [Related]
16. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Kuroda T; Rabkin SD; Martuza RL Cancer Res; 2006 Oct; 66(20):10127-35. PubMed ID: 17047077 [TBL] [Abstract][Full Text] [Related]
17. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Fu X; Zhang X Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088 [TBL] [Abstract][Full Text] [Related]
18. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599 [TBL] [Abstract][Full Text] [Related]
19. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503 [TBL] [Abstract][Full Text] [Related]
20. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]